Pfizer (PFE) Income towards Parent Company (2009 - 2026)

Pfizer (PFE) has reported Income towards Parent Company for 18 consecutive years, with -$13.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company changed N/A year-over-year to -$13.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 33.33% YoY), while the FY2025 annual figure was $25.0 million, up 127.27% from the prior year.
• Income towards Parent Company declined to -$13.0 million in Q1 2026 per PFE's latest filing, from $25.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $34.0 million in Q3 2022 and bottomed at -$26.0 million in Q4 2023.
• Historically, Income towards Parent Company has averaged $1.4 million across 5 years, with a median of -$3.5 million in 2023.
• Annual changes were most pronounced in 2022 — Income towards Parent Company slumped 1000.0% — and 2024, when it soared 950.0%.
• Pfizer's Income towards Parent Company stood at $34.0 million in 2022, then plunged by 176.47% to -$26.0 million in 2023, then jumped by 69.23% to -$8.0 million in 2024, then surged by 412.5% to $25.0 million in 2025, then slumped by 152.0% to -$13.0 million in 2026.
• Business Quant data shows PFE's Income towards Parent Company at -$13.0 million in Q1 2026, $25.0 million in Q2 2025, and -$8.0 million in Q3 2024.